西安环球印务股份有限公司 2017 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人李移岭、主管会计工作负责人林蔚及会计机构负责人(会计主管 人员)夏美莹声明：保证季度报告中财务报表的真实、准确、完整。 1 西安环球印务股份有限公司 2017 年第三季度报告 2017 年 10 月 西安环球印务股份有限公司 2017 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 678,914,976.62 | 692,618,350.12 | | -1.98% | | 归属于上市公司股东的净资产 | 511,554,643.23 | 516,097,846.94 | | -0.88% | | ...

Financial Performance - The company's operating revenue for the first half of 2017 was RMB 221,364,052.60, representing a 15.72% increase compared to RMB 191,290,823.76 in the same period last year[16]. - The net profit attributable to shareholders of the listed company decreased by 19.38% to RMB 12,953,331.38 from RMB 16,067,385.34 year-on-year[16]. - Basic and diluted earnings per share both decreased by 18.18% to RMB 0.09 from RMB 0.11 in the same period last year[16]. - The company reported a total revenue of 500 million RMB for the first half of 2017, representing a 15% increase year-over-year[97]. - The company expects a revenue growth of 10% for the second half of 2017, driven by new product launches and market expansion strategies[97]. Cash Flow and Assets - The net cash flow from operating activities dropped significantly by 72.25% to RMB 5,245,033.73, down from RMB 18,901,618.43 in the previous year[16]. - The company reported a cash balance of 76.93 million yuan at the end of the period, a decrease of 31.39% due to cash dividends of 20 million yuan and the use of raised funds[26]. - Cash and cash equivalents decreased by 18.68% to ¥76.93 million, accounting for 11.44% of total assets[56]. - The total assets at the end of the reporting period were RMB 672,260,002.71, a decrease of 2.94% from RMB 692,618,350.12 at the end of the previous year[17]. - The company's total assets decreased from 692,618,350.12 RMB at the beginning of the period to 672,260,002.71 RMB at the end of the period, a decline of approximately 2.6%[161]. Investments and R&D - Research and development investment increased by 26.98% to 10,796,586.65 CNY, emphasizing the company's commitment to innovation[46]. - The company plans to continue expanding its market presence and invest in new technologies to drive future growth[173]. - The company has committed to invest ¥7.88 million in the Tianjin project for producing 1.8 billion pharmaceutical packaging units, with 83.54% of the investment completed[69]. Market Position and Strategy - The company aims to expand its product line towards high value-added products and maintain its position in the Chinese pharmaceutical packaging industry[37]. - The company is actively pursuing market expansion opportunities in the high-tech packaging sector, particularly in response to government initiatives[40]. - The company plans to expand its market share by establishing large-scale production bases in key regions such as the Bohai Rim and Yangtze River Delta[37]. Risks and Challenges - The pharmaceutical packaging business is expected to see a decline in profitability due to rising costs of raw materials and labor[79]. - The company faces risks from the competitive landscape in the pharmaceutical packaging industry, with increasing pressure from both domestic and international competitors[81]. - Fluctuations in the prices of main raw materials, such as white cardboard and whiteboard paper, could significantly impact production costs and profitability[83]. Shareholder and Corporate Governance - The company plans not to distribute cash dividends or issue bonus shares, nor to increase capital using reserves[5]. - The company has committed to maintaining a dividend payout ratio of 40% for the fiscal year 2017[97]. - The company will provide quarterly updates on its performance and strategic initiatives to ensure transparency with investors[97]. - The company will publicly disclose reasons for any failure to fulfill commitments at shareholder meetings and through designated media[99]. Related Party Transactions - Shaanxi Pharmaceutical Holdings Group Co., Ltd. holds a 65% stake in Xi'an Global Printing Co., Ltd. and commits to avoiding and minimizing related party transactions with it[103]. - The company will ensure that all necessary transactions with Xi'an Global Printing and its subsidiaries will adhere to market principles, ensuring fairness and reasonable pricing[103]. Compliance and Legal Matters - The semi-annual report for the company has not been audited[107]. - There are no significant litigation or arbitration matters during the reporting period[109]. - The company has no penalties or rectification situations during the reporting period[111].

Financial Performance - The company's operating revenue for 2016 was ¥387,502,466.93, a decrease of 3.13% compared to ¥400,003,693.52 in 2015[14]. - The net profit attributable to shareholders for 2016 was ¥26,795,985.32, down 23.09% from ¥34,841,328.99 in 2015[14]. - The net profit after deducting non-recurring gains and losses was ¥22,658,445.14, a decline of 34.72% from ¥34,709,675.00 in 2015[14]. - The net cash flow from operating activities was ¥41,266,281.93, a decrease of 34.60% compared to ¥63,098,085.47 in 2015[14]. - Basic earnings per share for 2016 were ¥0.31, down 32.61% from ¥0.46 in 2015[14]. - Total revenue for 2016 was approximately ¥387.50 million, a decrease of 3.13% compared to ¥400.00 million in 2015[57]. - Revenue from the paper and paper products industry accounted for 99.38% of total revenue, with a year-on-year decline of 3.20%[57]. - The gross profit margin for the paper and paper products industry was 20.85%, down 2.41% from the previous year[59]. - The company reported a significant increase in revenue from the Central South region, which rose by 77.30% to ¥25.12 million[57]. - The company experienced an 81.88% increase in revenue from international markets, reaching ¥10.51 million[57]. Assets and Liabilities - The total assets at the end of 2016 were ¥692,618,350.12, an increase of 18.06% from ¥586,648,641.54 at the end of 2015[14]. - The net assets attributable to shareholders increased by 61.85% to ¥516,097,846.94 from ¥318,877,333.27 in 2015[17]. - The accounts receivable balance at the end of 2016 was RMB 121.80 million, accounting for 31.43% of the revenue and 17.59% of total assets, indicating a significant risk of bad debts if customer conditions deteriorate[108]. - The proportion of accounts receivable decreased by 2.37% to 17.59% of total assets, indicating improved cash management[78]. - The asset-liability ratio decreased compared to the beginning of the reporting period[172]. Dividends and Shareholder Returns - The company plans to distribute a cash dividend of ¥2.00 per 10 shares, along with a bonus share issue of 5 shares for every 10 shares held[4]. - The net profit for 2016 was RMB 26.80 million, with distributable profits amounting to RMB 239.03 million, resulting in a cash dividend payout ratio of 28.57%[116]. - The company has committed to maintaining a minimum cash dividend ratio of 20% during its growth phase[115]. - The cash dividend distribution plan is subject to approval at the 2016 annual general meeting[116]. - The company has not proposed any cash dividend distribution plans in the previous two years, indicating a shift in policy for 2016[114]. Research and Development - The company emphasizes a focus on research and development, aiming to enhance its core competitiveness through innovative packaging solutions[40]. - The company has established a comprehensive R&D system, supported by an experienced team, to improve product design and production efficiency[40]. - The company's R&D investment increased by 6.76% to ¥19,112,238.06 in 2016, representing 4.93% of total revenue, up from 4.48% in 2015[71]. - Research and development efforts focused on packaging for pharmaceutical products, electronic consumer goods, and health products, indicating a commitment to innovation[69]. - The company has developed advanced anti-counterfeiting technologies, including the application of holographic positioning hot stamping and digital discrete anti-counterfeiting technology[33][34]. Market Position and Strategy - The company maintained its leading position in the domestic pharmaceutical packaging industry, being a key independent supplier of pharmaceutical folding cartons[33]. - The company plans to expand its production bases in key pharmaceutical regions, leveraging its experience to increase market share[29]. - The company is focusing on expanding its market share in the pharmaceutical packaging sector while also venturing into electronic consumer product packaging[50]. - The company has developed two advanced automated production lines for electronic consumer product packaging, enhancing its service offerings to clients like ZTE and Samsung[44][50]. - The company plans to increase its production capacity of pharmaceutical folding cartons to over 4 billion units per year following the implementation of its fundraising projects[102]. Financial Management and Capital Structure - The company completed its initial public offering, raising a net amount of 168.80 million yuan, further optimizing its capital structure[48]. - The total cash inflow from financing activities rose by 105.23% to ¥289,278,921.47, attributed to funds raised from the company's IPO[75]. - The company's cash and cash equivalents increased significantly by 8,245.80% to ¥56,253,413.85, also due to IPO proceeds[75]. - The company raised a total of RMB 199.5 million from the public offering, with a net amount of RMB 168.8 million after deducting issuance costs of RMB 30.7 million[84]. - The balance of the raised funds account at the end of the reporting period was RMB 16.77 million, including interest income and fees[84]. Corporate Governance and Compliance - The company has committed to avoiding any activities that may compete with its business during its shareholding period[120]. - The company will ensure that controlled entities comply with the same obligations to avoid competition[120]. - The company will publicly disclose reasons for any failure to fulfill commitments and will apologize to shareholders and investors[120]. - The company has committed to maintaining stock price stability and protecting the interests of small investors, with penalties for non-compliance[126]. - The company will actively take legal measures to fulfill its commitments regarding information disclosure and accept supervision from regulatory authorities[128]. Social Responsibility and Investor Relations - The company actively engaged in social responsibility initiatives, including support for poverty alleviation and community welfare projects[158][159]. - The company maintained a 100% response rate to investor inquiries through various communication channels, enhancing transparency and protecting investor rights[159]. - The company did not conduct any investor relations activities during the reporting period[109]. Shareholder Structure and Management - The shareholder structure includes 19,397 total shareholders, with significant holdings by state-owned entities and foreign investors[175]. - The largest shareholder, Shaanxi Pharmaceutical Holdings Group Co., Ltd., holds 46.25% of the shares, amounting to 46,250,000 shares[175]. - The company's board of directors includes members with extensive experience in management and finance, such as the chairman who has been with the company since 2001[188][190]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 3.45 million yuan[200]. - The highest remuneration was received by the chairman, Li Yiling, totaling 796,900 yuan[200].

2017 年 4 月 1 西安环球印务股份有限公司 2017 年第一季度报告正文 证券代码：002799 证券简称：环球印务 公告编号：2017-019 西安环球印务股份有限公司 2017 年第一季度报告正文 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 西安环球印务股份有限公司 2017 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人李移岭、主管会计工作负责人及会计机构负责人林蔚声明：保 证季度报告中财务报表的真实、准确、完整。 2 西安环球印务股份有限公司 2017 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 105,726,713.91 | 88,828,812.70 | 19.02% | | 归属于上 ...

Financial Performance - Total assets at the end of the reporting period reached ¥674,807,551.22, an increase of 15.03% compared to the previous year[5] - Net assets attributable to shareholders of the listed company amounted to ¥505,900,162.43, reflecting a significant increase of 58.65% year-on-year[5] - Operating revenue for the reporting period was ¥86,396,453.54, representing a growth of 6.99% compared to the same period last year[5] - Net profit attributable to shareholders of the listed company was ¥530,915.47, showing a decrease of 10.83% year-to-date[5] - Basic earnings per share for the reporting period was ¥0.01, a 150.00% increase compared to the previous period, although it decreased by 20.00% year-to-date[5] - The weighted average return on net assets was 0.11%, down from 4.32% in the previous year[5] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,730[10] - The largest shareholder, Shaanxi Pharmaceutical Holdings Group Co., Ltd., held 46.25% of the shares[10] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[12] Cash Flow and Assets - Cash and cash equivalents increased by 114.78% to ¥117,039,895.95 due to the issuance of 25 million shares and the receipt of raised funds[15] - Accounts receivable decreased by 55.53% to ¥12,727,930.77 primarily due to a reduction in accepted bills[15] - Construction in progress surged by 853.58% to ¥22,062,729.05, mainly for the procurement of key production equipment[15] - Long-term borrowings decreased by 100% to ¥0 as the subsidiary replaced project loans with raised funds[15] - Operating income from non-operating activities rose by 717.23% to ¥1,698,405.46, mainly due to increased government subsidies[15] - Cash received from other operating activities increased by 335.67% to ¥3,021,005.25, primarily from government subsidies[15] - Cash received from investment income dropped by 100% to ¥0 as no dividends were received this period[15] - Cash paid for the purchase of fixed assets increased by 186.42% to ¥29,475,669.27, reflecting higher payments for key production equipment[15] - Total capital reserve increased by 4986.45% to ¥148,340,922.48 due to the issuance of new shares[15] - Cash received from financing activities surged by 8340.00% to ¥168,800,000.00, primarily from the issuance of 25 million shares[15] Regulatory Compliance and Commitments - The company will reduce its shareholding in the issuer after 3 trading days, complying with relevant laws and regulations[20] - If the issuer's stock price closes below the latest audited net asset value per share for 20 consecutive trading days within three years post-listing, the company will fulfill its obligations to stabilize the stock price[20] - The company commits to taking legal measures to fulfill all promises made regarding the initial public offering and will accept supervision from regulatory authorities and the public[22] - If the company fails to fulfill its commitments regarding shareholding and reduction, the proceeds from the reduction will belong to the issuer, and the company will extend the lock-up period by 6 months[22] - The company will actively take measures to stabilize the stock price and protect the interests of small investors, as per the stabilization plan[22] - The company will notify the issuer in writing of any intended share reductions, which will be publicly announced by the issuer[22] - The company will bear civil compensation responsibilities if there are false records or misleading statements in the prospectus that cause investor losses[22] - The company will temporarily withhold any cash dividends payable to it until it fulfills its commitments[20] - The company will ensure timely and accurate disclosure of information regarding shareholding and reduction intentions[22] - The company will accept corresponding responsibilities if it fails to fulfill its commitments regarding the prospectus[22] Compliance with Regulations - The company committed to unconditionally bear any costs arising from past non-compliance with housing fund management regulations, ensuring no economic loss to the issuer[24] - The company pledged to fully cover any expenses related to social insurance compliance issues, preventing financial losses for the issuer and its subsidiaries[24] - The company has implemented measures to ensure the fulfillment of earnings per share recovery commitments, including constraints on executive consumption behaviors[26] - The company has committed to not engage in any activities that would constitute competition with its subsidiaries, ensuring protection of shareholder interests[26] - The company will prioritize acquisition or management of any competing business activities to safeguard its operational integrity[26] - The company has established a long-term commitment to comply with regulations regarding related party transactions, ensuring transparency and accountability[27] - The company is focused on enhancing its compensation system to align with earnings recovery measures, supporting board and compensation committee initiatives[26] - The company has committed to actively promote the implementation of measures that align with regulatory requirements for earnings recovery[26] - The company will publicly disclose any failure to fulfill commitments and provide explanations to shareholders and the public[26] - The company has established a framework to ensure that any new business activities do not conflict with existing operations, maintaining competitive integrity[26] Business Outlook - The estimated net profit attributable to shareholders for 2016 is expected to range from 26.13 million to 34.84 million CNY, reflecting a decrease of 25% to 0% compared to 2015[30] - The main business of pharmaceutical packaging is currently in a stable development phase, maintaining stable profitability[30] - The company has begun to enter the electronic consumer goods packaging sector, obtaining qualified supplier status from major companies like Samsung and ZTE, leading to an increase in order volume[30] - The decline in profits from liquor packaging and corrugated paper packaging is attributed to national policies and industry downturns, as well as low levels of scale[30] - The company has committed to avoiding and reducing related party transactions with its subsidiary, ensuring fair market practices[28]

Financial Performance - The company's operating revenue for the first half of 2016 was ¥191,290,823.76, a decrease of 9.53% compared to ¥211,452,182.08 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was ¥16,067,385.34, down 19.19% from ¥19,882,087.03 year-on-year[20]. - The net profit after deducting non-recurring gains and losses was ¥15,124,714.30, reflecting a decline of 23.40% compared to ¥19,744,415.11 in the previous year[20]. - The net cash flow from operating activities was ¥18,901,618.43, a significant drop of 36.92% from ¥29,964,731.77 in the same period last year[20]. - Basic earnings per share decreased by 40.74% to ¥0.16 from ¥0.27 in the previous year[20]. - The company reported a total profit of CNY 18,540,350.25, down 20.0% from CNY 23,155,529.74 in the same period last year[52]. - The company’s sales expenses increased to CNY 13,728,059.01, up 7.2% from CNY 12,798,921.29 in the previous year[52]. - Investment income for the period was CNY 3,206,985.35, a slight decrease from CNY 3,391,329.49 in the same period last year[52]. - The company’s financial expenses decreased to CNY 4,287,821.06, down 23.0% from CNY 5,562,592.03 in the previous year[52]. Assets and Liabilities - Total assets increased by 33.40% to ¥782,607,545.32 from ¥586,648,641.54 at the end of the previous year[20]. - The company's total liabilities amounted to CNY 278,862,826.71, up from CNY 267,771,308.27, reflecting a growth of about 3.9%[156]. - Shareholders' equity increased to CNY 503,744,718.61 from CNY 318,877,333.27, showing a growth of approximately 57.9%[158]. - Current assets totaled CNY 446,476,143.25, compared to CNY 252,772,486.46 at the beginning of the period, indicating a rise of about 76.5%[154]. - Cash and cash equivalents rose significantly to CNY 235,741,092.89 from CNY 54,493,196.61, marking an increase of approximately 333.5%[153]. Capital Structure and Shareholder Information - The company completed its initial public offering, raising a net amount of CNY 168.80 million, further optimizing its capital structure[30]. - The total number of shares increased from 75 million to 100 million, with the proportion of limited sale shares decreasing from 65% to 48.75%[134]. - The largest shareholder, Shaanxi Pharmaceutical Holdings Group, holds 46.25% of the shares, a decrease of 2.5 million shares during the reporting period[138]. - The company has 65% of its shares held by Shaanxi Pharmaceutical Holdings Group, which has committed to avoiding and minimizing related party transactions with the company[123]. - The company reported a total of 1,554.02 million yuan in related party transactions during the reporting period, accounting for 3,000 million yuan in approved transaction amounts[79]. Research and Development - Research and development investment decreased by 18.37% to CNY 1.50 million[32]. - The company has a total of 71 R&D personnel, with 6 core technical staff having over 15 years of industry experience, enhancing its R&D capabilities[43]. - The company has established cooperative R&D relationships with advanced equipment suppliers to enhance production technology[43]. Governance and Compliance - The company maintained good governance practices, ensuring transparency and compliance with relevant laws and regulations[69]. - There were no major litigation or arbitration matters during the reporting period[70]. - The company has not faced any penalties or rectification issues during the reporting period[128]. - The half-year financial report has not been audited[127]. Future Plans and Commitments - The company plans to expand its production bases in key pharmaceutical regions, leveraging electronic supervision code policies to increase market share[30]. - The company plans to focus on market expansion and new product development to improve future performance[52]. - The company is committed to transparency and will disclose any unfulfilled commitments to shareholders and the public[108]. - The company will accept supervision from regulatory authorities and the public regarding its commitments[106]. Cash Flow and Financing Activities - The net cash flow from financing activities was 172,320,600.50 CNY, compared to a negative cash flow of -31,937,072.77 CNY in the previous period, indicating a significant improvement[177]. - The company reported a total cash inflow from financing activities of 218,500,000.00 CNY, significantly higher than 48,794,621.24 CNY in the previous period, highlighting successful fundraising efforts[180]. - The total cash outflow from financing activities was 31,795,840.01 CNY, down from 76,377,914.61 CNY in the prior period, suggesting improved cash management[180].

Financial Performance - The company's operating revenue for the first half of 2016 was ¥191,290,823.76, a decrease of 9.53% compared to ¥211,452,182.08 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was ¥16,067,385.34, down 19.19% from ¥19,882,087.03 year-on-year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥15,124,714.30, a decline of 23.40% compared to ¥19,744,415.11 in the previous year[21]. - The net cash flow from operating activities was ¥18,901,618.43, representing a decrease of 36.92% from ¥29,964,731.77 in the same period last year[21]. - The basic earnings per share were ¥0.16, down 40.74% from ¥0.27 in the previous year[21]. - The company reported a revenue of 191.29 million yuan for the first half of 2016, a decrease of 9.53% year-on-year[32]. - The net profit attributable to shareholders was 16.07 million yuan, down 19.19% compared to the previous year[32]. - The company reported a total comprehensive income of CNY 16,067,385.34, down from CNY 19,882,087.03, indicating a decrease of about 19.0%[158]. - The total operating costs for the current period were CNY 177,066,483.61, down from CNY 191,865,948.80, reflecting a decrease of about 7.8%[155]. Assets and Liabilities - Total assets at the end of the reporting period were ¥782,607,545.32, an increase of 33.40% from ¥586,648,641.54 at the end of the previous year[21]. - The company's total assets reached CNY 617,982,786.43, up from CNY 425,594,781.21, which is an increase of approximately 45.2%[154]. - Total liabilities increased to ¥278,862,826.71 from ¥267,771,308.27, showing a rise of about 4%[147]. - The company's current liabilities totaled ¥214,218,439.23, up from ¥193,126,920.79, which is an increase of about 11%[146]. - The company's equity attributable to shareholders rose to ¥503,744,718.61 from ¥318,877,333.27, marking an increase of approximately 58%[149]. Cash Flow - The company's cash and cash equivalents increased to ¥235,741,092.89 from ¥54,493,196.61, representing a growth of approximately 333%[143]. - Cash inflow from financing activities totaled ¥244,500,000.00, compared to ¥73,794,621.24 in the previous period, an increase of approximately 231%[166]. - The net cash flow from operating activities was -$8,517,477.74, a decrease from $19,151,966.61 in the previous period, indicating a significant decline in operational performance[170]. - The total cash and cash equivalents at the end of the period reached $197,061,659.79, up from $26,083,969.02, indicating improved liquidity[172]. Share Capital and Equity - The company issued 25 million new shares at a price of 7.98 RMB per share, raising a net amount of 168.8 million RMB[125]. - After the issuance, the total share capital increased from 75 million shares to 100 million shares, with 75 million shares subject to restrictions and 25 million shares unrestricted[122]. - The company's net assets increased by 168.8 million RMB following the issuance of new shares[126]. - The capital reserve increased by 143.8 million RMB as a result of the share issuance[125]. - Major shareholders holding more than 5% of shares did not experience significant changes in their holdings post-issuance[122]. Strategic Plans and Market Position - The company aims to expand its market share by establishing large-scale production bases in key pharmaceutical regions[31]. - The company plans to enhance its position in the pharmaceutical packaging industry and become a preferred partner for multinational pharmaceutical companies in China[30]. - The company has maintained its competitive edge in the pharmaceutical packaging sector, being a leading independent supplier in China[42]. - The company plans to continue its growth strategy, focusing on capital increases and equity management[186]. Governance and Compliance - The company has maintained good governance practices, ensuring transparency and equal rights for all shareholders[74]. - The company has not experienced any significant changes in project feasibility during the reporting period[61]. - There were no major litigation or arbitration matters reported during the period[76]. - The company has committed to strict adherence to regulations regarding share reduction and will notify the issuer of any intended share sales[103]. Research and Development - Research and development expenses decreased by 18.37% to 1.50 million yuan[34]. - The company continues to focus on R&D, employing 71 research personnel, including 6 core technical staff with over 15 years of industry experience[46].